3rd Feb 2006 07:00
Celsis International PLC03 February 2006 CELSIS INTERNATIONAL PLC Celsis Wins New Contracts with URL Mutual Pharmaceutical Company and Procter & Gamble Company 3 February 2006: Celsis International plc ("Celsis"), announces that itsLaboratory Group has won new contracts with URL Mutual Pharmaceutical Companyand Procter & Gamble Company for the provision of contract testing services. URL Mutual Pharmaceutical Company Celsis Laboratory Group has entered into an agreement with URL MutualPharmaceutical Company to supply contract testing services in support of productrelease for Mutual's extensive list of generic pharmaceutical products. CelsisLaboratory Group will provide Mutual with analytical chemistry and stabilityservices enabling Mutual to ensure the stability and chemical composition of itsproducts. This contract is expected to generate in excess of $1.5 million perannum in additional revenue for the Lab Group. URL Mutual Pharmaceutical Company, a leading generic drug manufacturer based inPhiladelphia, Pennsylvania, has been a leading national supplier of genericpharmaceuticals for over 50 years and manufactures and distributes one of themost extensive product lines in the generic industry. Procter & Gamble Company Celsis Laboratory Group has also been contracted by Procter & Gamble Company(Consumer Health Division) to supply full release testing for a new productlaunch. The analytical services provided by Celsis include analyticalchemistry, microbiology and sensory analysis in support of new productmanufacturing later this Spring. This contract is expected to generate inexcess of $500,000 per annum in incremental revenue for Celsis' LaboratoryGroup. Procter & Gamble, one of the world's leading consumer product companies,provides products and services to consumers in 140 countries and has nearly98,000 people. They have operations in almost 80 countries around the worldproducing many household brands, including health products such as Vicks andPepto-Bismol. In the year to 31 March 2005, Celsis' Laboratory Group represented 48% of totalGroup revenues - producing revenues of $14.6 million, compared with $13.6million in the previous period. Jay LeCoque, Chief Executive Officer of Celsis said: "We are pleased to announce that both Mutual and Procter & Gamble have chosenCelsis as their analytical services provider. These agreements demonstrate thatour business strategies are working and that our commitment to providingcustomer focused services has established Celsis Laboratory Group as one of theleading analytical service providers in the pharmaceutical industry. This new agreement with Procter & Gamble also highlights the increasingsynergies between our Product and Laboratory Groups. The Product Group hasenjoyed an excellent relationship with Procter & Gamble for years and has morerecently been working closely with P&G to develop customised capabilities fromthe Laboratory Group. We look forward to seeing further agreements to strengthen Celsis' position inour respective markets." Enquiries: Celsis Laboratory Group Tel: 001 732 346 5100Rich Segiel, Director Business Development Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Ben AtwellDavid Yates Celsis International plc Celsis International plc is a rapid microbial detection and analytical servicescompany. The company is listed on the London Stock Exchange (CEL.L). Using proprietary technology, the Product Group is the world leader in theprovision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical and biopharmaceuticalcompanies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Celadon Pharmaceuticals